Natalia de las Heras

Prof. Dr. Natalia de las Heras

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2008 in Blood
Verified
Journal Article
Open access
PDF file
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
MVMaría-Belén Vidriales
María-Belén Vidriales
JCJorge Cerveró
Jorge Cerveró
GMGema Mateo
Gema Mateo
JPJose J. Pérez
Jose J. Pérez
JMJesús F. San Miguel
Jesús F. San Miguel
Minimal residual disease (MRD) assessment is standard in many hematologic malignancies but is considered investigational in multiple myeloma (MM). We report a prospective analysis of the prognostic importance of MRD detection by multiparameter flow cytometry (MFC) in 295 newly diagnosed MM patients uniformly treated in the GEM2000 protocol VBMCP/VBAD induction plus autologous stem cell transplantation [ASCT]). MRD status by MFC was determined at day 100 after ASCT. Progression-free survival (PFS; median 71 vs 37 months, P < .001) and overall survival (OS; median not reached vs 89 months, P = .002) were longer in patients who were MRD negative versus MRD positive at day 100 after ASCT. Similar prognostic differentiation was seen in 147 patients who achieved immunofixation-negative complete response after ASCT. Moreover, MRD− immunofixation-negative (IFx−) patients and MRD− IFx+ patients had significantly longer PFS than MRD+ IFx− patients. Multivariate analysis identified MRD status by MFC at day 100 after ASCT as the most important independent prognostic factor for PFS (HR = 3.64, P = .002) and OS (HR = 2.02, P = .02). Our findings demonstrate the clinical importance of MRD evaluation by MFC, and illustrate the need for further refinement of MM re-sponse criteria. This trial is registered at http://clinicaltrials.gov under identifier NCT00560053.

22 July 2013 in International Journal of Hypertension
Verified
Journal Article
Open access
PDF file
NRNicolás F. Renna
Nicolás F. Renna
NHNatalia de las Heras
Natalia de las Heras
RMRoberto M. Miatello
Roberto M. Miatello
Vascular remodeling refers to alterations in the structure of resistance vessels contributing to elevated systemic vascular resistance in hypertension. We start with some historical aspects, underscoring the importance of Glagov’s contribution. We then move to some basic concepts on the biomechanics of blood vessels and explain the definitions proposed by Mulvany for specific forms of remodeling, especially inward eutrophic and inward hypertrophic. The available evidence for the existence of remodeled resistance vessels in hypertension comes next, with relatively more weight given to human, in comparison with animal data. Mechanisms are discussed. The impact of antihypertensive drug treatment on remodeling is described, again with emphasis on human data. Some details are given on the three mechanisms to date which point to remodeling resistance arteries as an independent predictor of cardiovascular risk in hypertensive patients. We terminate by considering the potential role of remodeling in the pathogenesis of endorgan damage and in the perpetuation of hypertension.

23 February 2017 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
VLVicente Lahera
Vicente Lahera
NHNatalia de las Heras
Natalia de las Heras
ALAntonio López-Farré
Antonio López-Farré
Walter ManuchaWalter Manucha
Walter Manucha
LFLeón Ferder
León Ferder

6 July 2012 in Haematologica
Verified
Journal Article
Open access
PDF file
RMR. J. Pessoa de Magalhaes
R. J. Pessoa de Magalhaes
MVMaría-Belén Vidriales
María-Belén Vidriales
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
CFC. Fernandez-Gimenez
C. Fernandez-Gimenez
Ramon Garcia-SanzRamon Garcia-Sanz
Ramon Garcia-Sanz
AOAlberto Orfao
Alberto Orfao
Multiple myeloma remains largely incurable. However, a few patients experience more than 10 years of relapse-free survival and can be considered as operationally cured. Interestingly, long-term disease control in multiple myeloma is not restricted to patients with a complete response, since some patients revert to having a profile of monoclonal gammopathy of undetermined significance. We compared the distribution of multiple compartments of lymphocytes and dendritic cells in the bone marrow and peripheral blood of multiple myeloma patients with long-term disease control (n=28), patients with newly diagnosed monoclonal gammopathy of undetermined significance (n=23), patients with symptomatic multiple myeloma (n=23), and age-matched healthy adults (n=10). Similarly to the patients with monoclonal gammopathy of undetermined significance and symptomatic multiple myeloma, patients with long-term disease control showed an expansion of cytotoxic CD8+ T cells and natural killer cells. However, the numbers of bone marrow T-regulatory cells were lower in patients with long-term disease control than in those with symptomatic multiple myeloma. It is noteworthy that B cells were depleted in patients with monoclonal gammopathy of undetermined significance and in those with symptomatic multiple myeloma, but recovered in both the bone marrow and peripheral blood of patients with long-term disease control, due to an increase in normal bone marrow B-cell precursors and plasma cells, as well as pre-germinal center peripheral blood B cells. The number of bone marrow dendritic cells and tissue macrophages differed significantly between patients with long-term disease control and those with symptomatic multiple myeloma, with a trend to cell count recovering in the former group of patients towards levels similar to those found in healthy adults. In summary, our results indicate that multiple myeloma patients with long-term disease control have a constellation of unique immune changes favoring both immune cytotoxicity and recovery of B-cell production and homing, suggesting improved immune surveillance.

1 January 2007 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
VLVicente Lahera
Vicente Lahera
MGMarian Goicoechea
Marian Goicoechea
SVSoledad Garcia de Vinuesa
Soledad Garcia de Vinuesa
MMMaria Miana
Maria Miana
NHNatalia de las Heras
Natalia de las Heras
JLJose Luno
Jose Luno
Atherosclerosis and its complications represent the major cause of death in developed countries. Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A [HMGCoA] reductase and consequently inhibitors of cholesterol biosynthesis. Statins have been described as the most potent class of drugs to reduce serum cholesterol levels. In clinical trials, statins are beneficial in primary and secondary prevention of coronary heart disease. Statins, were initially designed as cholesterol-lowering drugs. However, these drugs, besides their lipid-lowering properties, exert a number of protective effects on the cardiovascular system that emerged over the past years. The benefits observed with statin treatment appear to be greater than that might be expected from reduction in lipid levels alone, suggesting effects beyond cholesterol lowering. These cholesterol-independent effects have been called “pleiotropic”. The cholesterol-independent or “pleiotropic” effects of statins involve improvement of endothelial function, stability of atherosclerotic plaques, decrease of oxidative stress and inflammation, and inhibition of thrombogenic response. These pleiotropic effects of statins have been proposed as key properties of these drugs to reduce cardiovascular morbidity and mortality. The present review will emphasize the molecular mechanisms underlying the effects of statins on endothelial function and oxidative stress. In particular, inhibition of small GTP-binding proteins, Rho, Ras and Rac, which are regulated by isoprenoids [farnesyl pyrophosphate and geranylgeranyl pyrophosphate], seems to play an important role in mediating the pleiotropic effects of statins.

14 November 2008 in Energy & Environmental Science
Verified
Journal Article
Closed access
PDF file
NHNatalia de las Heras
Natalia de las Heras
EREdward Roberts
Edward Roberts
RLR. Langton
R. Langton
DHD. R. Hodgson
D. R. Hodgson
In this paper we review the range of materials which have been studied for use as separator plates in automotive PEM fuel cells, with particular emphasis on metals. For commercial application separator plates must be resistant to corrosion, durable and offer low contact resistance in a fuel cell stack. Graphite and carbon composite materials have been widely used, as they offer durability and give reliable performance. For portable and transport applications, new materials offering reduced cost, weight and volume are needed. Metal plates may offer a compact, low cost alternative to graphite and carbon based composites. However in the aggressive fuel cell environment, corrosion of metal plates can significantly effect fuel cell performance while passivation can also lead to increased ohmic losses. The only metal plate material studied in the literature which meets the performance targets for contact resistance and corrosion is gold coated stainless steel. New corrosion resistant coatings are being developed in order to address these significant issues and this review paper evaluates them in the context of the DOE targets established for 2010.